180 related articles for article (PubMed ID: 24690257)
1. In vitro transport characteristics of EFdA, a novel nucleoside reverse transcriptase inhibitor using Caco-2 and MDCKII cell monolayers.
Zhang W; Parniak MA; Sarafianos SG; Empey PE; Rohan LC
Eur J Pharmacol; 2014 Jun; 732():86-95. PubMed ID: 24690257
[TBL] [Abstract][Full Text] [Related]
2. Preformulation studies of EFdA, a novel nucleoside reverse transcriptase inhibitor for HIV prevention.
Zhang W; Parniak MA; Mitsuya H; Sarafianos SG; Graebing PW; Rohan LC
Drug Dev Ind Pharm; 2014 Aug; 40(8):1101-11. PubMed ID: 23841536
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Drug Transport in MDCKII-Wild Type, MDCKII-MDR1, MDCKII-BCRP and Caco-2 Cell Lines.
Mukkavilli R; Jadhav G; Vangala S
Curr Pharm Biotechnol; 2017; 18(14):1151-1158. PubMed ID: 29521222
[TBL] [Abstract][Full Text] [Related]
4. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT).
Guo A; Marinaro W; Hu P; Sinko PJ
Drug Metab Dispos; 2002 Apr; 30(4):457-63. PubMed ID: 11901101
[TBL] [Abstract][Full Text] [Related]
5. 4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms.
Michailidis E; Huber AD; Ryan EM; Ong YT; Leslie MD; Matzek KB; Singh K; Marchand B; Hagedorn AN; Kirby KA; Rohan LC; Kodama EN; Mitsuya H; Parniak MA; Sarafianos SG
J Biol Chem; 2014 Aug; 289(35):24533-48. PubMed ID: 24970894
[TBL] [Abstract][Full Text] [Related]
6. The High Genetic Barrier of EFdA/MK-8591 Stems from Strong Interactions with the Active Site of Drug-Resistant HIV-1 Reverse Transcriptase.
Takamatsu Y; Das D; Kohgo S; Hayashi H; Delino NS; Sarafianos SG; Mitsuya H; Maeda K
Cell Chem Biol; 2018 Oct; 25(10):1268-1278.e3. PubMed ID: 30174310
[TBL] [Abstract][Full Text] [Related]
7. Probing the molecular mechanism of action of the HIV-1 reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) using pre-steady-state kinetics.
Muftuoglu Y; Sohl CD; Mislak AC; Mitsuya H; Sarafianos SG; Anderson KS
Antiviral Res; 2014 Jun; 106():1-4. PubMed ID: 24632447
[TBL] [Abstract][Full Text] [Related]
8. Stereoselective and concentration-dependent polarized epithelial permeability of a series of phosphoramidate triester prodrugs of d4T: an in vitro study in Caco-2 and Madin-Darby canine kidney cell monolayers.
Siccardi D; Kandalaft LE; Gumbleton M; McGuigan C
J Pharmacol Exp Ther; 2003 Dec; 307(3):1112-9. PubMed ID: 14557377
[TBL] [Abstract][Full Text] [Related]
9. Antiretroviral potency of 4'-ethnyl-2'-fluoro-2'-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes.
Njenda DT; Aralaguppe SG; Singh K; Rao R; Sönnerborg A; Sarafianos SG; Neogi U
J Antimicrob Chemother; 2018 Oct; 73(10):2721-2728. PubMed ID: 30053052
[TBL] [Abstract][Full Text] [Related]
10. Transport of decursin and decursinol angelate across Caco-2 and MDR-MDCK cell monolayers: in vitro models for intestinal and blood-brain barrier permeability.
Madgula VL; Avula B; Reddy V L N; Khan IA; Khan SI
Planta Med; 2007 Apr; 73(4):330-5. PubMed ID: 17372866
[TBL] [Abstract][Full Text] [Related]
11. Oral administration of the nucleoside EFdA (4'-ethynyl-2-fluoro-2'-deoxyadenosine) provides rapid suppression of HIV viremia in humanized mice and favorable pharmacokinetic properties in mice and the rhesus macaque.
Stoddart CA; Galkina SA; Joshi P; Kosikova G; Moreno ME; Rivera JM; Sloan B; Reeve AB; Sarafianos SG; Murphey-Corb M; Parniak MA
Antimicrob Agents Chemother; 2015 Jul; 59(7):4190-8. PubMed ID: 25941222
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor.
Michailidis E; Marchand B; Kodama EN; Singh K; Matsuoka M; Kirby KA; Ryan EM; Sawani AM; Nagy E; Ashida N; Mitsuya H; Parniak MA; Sarafianos SG
J Biol Chem; 2009 Dec; 284(51):35681-91. PubMed ID: 19837673
[TBL] [Abstract][Full Text] [Related]
13. 2'-deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants.
Kawamoto A; Kodama E; Sarafianos SG; Sakagami Y; Kohgo S; Kitano K; Ashida N; Iwai Y; Hayakawa H; Nakata H; Mitsuya H; Arnold E; Matsuoka M
Int J Biochem Cell Biol; 2008; 40(11):2410-20. PubMed ID: 18487070
[TBL] [Abstract][Full Text] [Related]
14. Potent activity of a nucleoside reverse transcriptase inhibitor, 4'-ethynyl-2-fluoro-2'-deoxyadenosine, against human immunodeficiency virus type 1 infection in a model using human peripheral blood mononuclear cell-transplanted NOD/SCID Janus kinase 3 knockout mice.
Hattori S; Ide K; Nakata H; Harada H; Suzu S; Ashida N; Kohgo S; Hayakawa H; Mitsuya H; Okada S
Antimicrob Agents Chemother; 2009 Sep; 53(9):3887-93. PubMed ID: 19546363
[TBL] [Abstract][Full Text] [Related]
15. Assessment of ABCG2-mediated transport of xenobiotics across the blood-milk barrier of dairy animals using a new MDCKII in vitro model.
Wassermann L; Halwachs S; Baumann D; Schaefer I; Seibel P; Honscha W
Arch Toxicol; 2013 Sep; 87(9):1671-82. PubMed ID: 23652544
[TBL] [Abstract][Full Text] [Related]
16. Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.
Nakata H; Amano M; Koh Y; Kodama E; Yang G; Bailey CM; Kohgo S; Hayakawa H; Matsuoka M; Anderson KS; Cheng YC; Mitsuya H
Antimicrob Agents Chemother; 2007 Aug; 51(8):2701-8. PubMed ID: 17548498
[TBL] [Abstract][Full Text] [Related]
17. The Permeation of Acamprosate Is Predominantly Caused by Paracellular Diffusion across Caco-2 Cell Monolayers: A Paracellular Modeling Approach.
Antonescu IE; Rasmussen KF; Neuhoff S; Fretté X; Karlgren M; Bergström CAS; Nielsen CU; Steffansen B
Mol Pharm; 2019 Nov; 16(11):4636-4650. PubMed ID: 31560549
[TBL] [Abstract][Full Text] [Related]
18. Delayed emergence of HIV-1 variants resistant to 4'-ethynyl-2-fluoro-2'-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001.
Maeda K; Desai DV; Aoki M; Nakata H; Kodama EN; Mitsuya H
Antivir Ther; 2014; 19(2):179-89. PubMed ID: 24162098
[TBL] [Abstract][Full Text] [Related]
19. Structural basis of HIV inhibition by translocation-defective RT inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA).
Salie ZL; Kirby KA; Michailidis E; Marchand B; Singh K; Rohan LC; Kodama EN; Mitsuya H; Parniak MA; Sarafianos SG
Proc Natl Acad Sci U S A; 2016 Aug; 113(33):9274-9. PubMed ID: 27489345
[TBL] [Abstract][Full Text] [Related]
20. 4'-Ethynyl-2-fluoro-2'-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor.
Markowitz M; Sarafianos SG
Curr Opin HIV AIDS; 2018 Jul; 13(4):294-299. PubMed ID: 29697468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
